Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Simbioflora
- Development stage
- Unknown
- Lead developer
- Farmoquímica
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Simbioflora is a synbiotic supplement composed of a proprietary blend of probiotic bacteria, including species of *Bifidobacterium* and *Lactobacillus*, combined with the prebiotic fiber fructooligosaccharides (FOS). It is primarily used to modulate the gastrointestinal microbiota, particularly in patients undergoing cancer treatments such as surgery or chemoradiotherapy. By promoting the growth of beneficial bacteria and inhibiting pathogens, Simbioflora aims to reduce systemic inflammatory markers like C-reactive protein (CRP) and interleukin-6 (IL-6), improve gut barrier function, and decrease the incidence of postoperative infectious complications. The product is developed and marketed by the Brazilian pharmaceutical company Farmoquimica (FQM).
- Brand names
- Simbioflora
- Other names
- synbioticprobiotic + prebiotic
02
Targets
IL-6 (Interleukin 6)
Beyond the preview
Go deeper on Simbioflora.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Simbioflora.